Pharmos - Worst Pharma Stocks of 2007

Company: Pharmos
Starting stock price: $1.85
Ending stock price: $0.34
Percent Change: -81.62%

Details: In January of 2007 Pharmos announced that it's Phase II trial of cannabinor, an intravenous therapy for pain, failed to hit its primary endpoint. A separate test for relieving pain associated with molar dental extractions is still ongoing. The company announced that it cut its workforce in Israel by 15--down to 8--in an effort to restructures and conserve cash. Pharmos is also it's considering bringing in new investors to finance the subsidiary as an independent operation.

More News:
Pharmos cuts staff at Israeli subsidiary. Report
Pharmos pain drug fails in Phase II. Report

Pharmos - Worst Pharma Stocks of 2007

Suggested Articles

The second of AbbVie’s highly anticipated 2019 blockbuster candidates is here: Its crucial Humira follow-up, Rinvoq.

Bristol-Myers Squibb’s takeover of Celgene hasn’t always gone smoothly, but now a once-left-for-dead centerpiece of that deal is ready to launch.

Investors sued Novo Nordisk in Denmark, claiming it misled the public about trouble plaguing its insulin franchise—and demanding $1.75B in damages.